• Home
  • NEW DAY MEDICINE
  • 3 (65) 2024
  • 53 -3 (65) 2024 - Musashaykhova Sh.M. Boboev K.T. - CHARACTERISTICS OF THE CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA

53 -3 (65) 2024 - Musashaykhova Sh.M. Boboev K.T. - CHARACTERISTICS OF THE CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA

CHARACTERISTICS OF THE CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA

Musashaykhova Sh.M. Andijan State Medical Institute

Boboev K.T. Republican Specialized Scientific and Practical Medical Hematology Center, Uzbekistan

Musashaykhov U.Х. Andijan State Medical Institute

Sattarov O.X. Andijan State Medical Institute

Resume

The materials for our research were 145 patients with AML who were in inpatient treatment at the Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan. Clinical and laboratory studies were performed at the Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan.

Keywords: platelets, erythrocytes, blast cells, acute myeloid leukemia, hyperleukocytosis, anemia.

First page

286

Last page

289

For citation: Musashaykhova Sh.M. Boboev K.T., Musashaykhov U.Х., Sattarov O.X. - CHARACTERISTICS OF THE CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA//New Day in Medicine 3(65)2024 286-289 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. // Blood Cancer J. 2015;5:e331.
  2. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. // N Engl J Med. 2015;373(16):1541–1552. doi: 10.1056/NEJMra1400972.
  3. Jonathan R Brestoff, John L Frater, Contemporary Challenges in Clinical Flow Cytometry: Small Samples, Big Data, Little Time, // The Journal of Applied Laboratory Medicine, 10.1093/jalm/jfab176, (2022).
  4. Kiyoi H. FLT3 inhibitors: recent advances and problems for clinical application. // Nagoya J Med Sci. 2015;77:7‐17.
  5. Ma L, Li X, Zhang J, et al. [Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2015;36:216-220.
  6. Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. // Clin Lymphoma Myeloma Leuk 2017; 17(8): 464–470.
  7. Rose D, Haferlach T, Schnittger S, et al. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. // Leukemia. 2017; 31:11-17.
  8. Sallman D.A., McLemore A.F., Aldrich A.L., Komrokji R.S., McGraw K.L., Dhawan A., Geyer S., Hou H.-A., Eksioglu E.A., Sullivan A., et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. // Blood. 2020; 136:2812–2823. doi: 10.1182/blood.2020006158.
  9. Sanchez R, Ayala R, Alonso RA, Martinez MP, Ribera J, Garcia O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, et al. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. // Ann Hematol. 2017; 96(7):1069–1075.
  10. Tasian SK, Teachey DT, Li Y. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. // Blood. 2017; 129(2):177-187.

    file

    download